NCT05640713View on ClinicalTrials.gov

Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy

PHASE1UnknownINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

February 1, 2025

Study Completion Date

August 1, 2025

Conditions
Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
Interventions
DRUG

ThisCART19A

ThisCART19A is a new type CAR-T therapy for patients with r/r B Cell Malignancy .

DRUG

Fludarabine Pill

Fludarabine is used for lymphodepletion.

DRUG

Cyclophosphamide

Cyclophosphamide is used for lymphodepletion.

DRUG

VP-16 Protocol

VP-16 is used for lymphodepletion.

Trial Locations (1)

Unknown

Henan cancer hospital, Zhengzhou

Sponsors
All Listed Sponsors
collaborator

Fundamenta Therapeutics, Ltd.

INDUSTRY

lead

Henan Cancer Hospital

OTHER_GOV

NCT05640713 - Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy | Biotech Hunter | Biotech Hunter